What's new?

Sofinnova Partners Raises €472 ($548) Million to Form Largest Early-Stage Healthcare VC Fund in Europe

European venture capital firm has raised €1 billion in the last 12 months across its expanding life science investment platform PARIS, France – October 19,¬ 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the close of its latest earl...

Sofinnova Partners raises €150M for its third industrial biotech fund dedicated to environmental impact

The fund will invest in companies leveraging biotechnology to develop sustainable solutions Sofinnova Industrial Biotech II is part of the VC firm’s pioneering strategy initiated over a decade ago PARIS, France – November 17, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in ...

Geraldine Usseglio Joins Sofinnova Partners as Head of Human Resources

Paris – October 28, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the appointment of Geraldine Usseglio as Head of Human Resources. The creation of this position reinforces the ongoing expansion of the firm’s teams and the diversif...

Sofinnova Partners congratulates portfolio company DNA Script for the success of its €142M ($165M) Oversubscribed Series C Fundraise

The new funds will help accelerate the commercialization of the company’s Enzymatic DNA Printing Platform Sofinnova Partners was the company’s first institutional investor and led its seed round in 2016  

Sofinnova Partners Raises €472 ($548) Million to Form Largest Early-Stage Healthcare VC Fund in Europe

European venture capital firm has raised €1 billion in the last 12 months across its expanding life science investment platform PARIS, France – October 19,¬ 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the close of its latest earl...

Sofinnova Partners announces three new investments from its fund dedicated to Italian scientific research

Key investments made through the Sofinnova Telethon Fund underscore the venture capital firm’s commitment to fostering a thriving Italian biotech ecosystem AAVantgarde Bio, Alia Therapeutics, and Borea Therapeutics are developing promising new therapies for rare, genetic disorders Milan, Italy – June 30, 2021 - Sof...

Medtech Accelerator Sofinnova MD Start III Launches a Call for early stage Medical Device Projects

PARIS, France – June 8, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its medtech accelerator, Sofinnova MD Start III, is launching a call for early-stage projects. Sofinnova MD Start III is part of the Sofinnova platform of f...

Sofinnova Partners closes €445M ($540M) oversubscribed late-stage healthcare crossover fund

The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – M...

Dr. Joe Anderson Joins Sofinnova Partners

Dr. Anderson’s appointment as Partner in the Crossover Fund reflects the venture capital firm’s continuing expansion across the entire value chain of life sciences investments, from seed to later-stage   PARIS, France – October 14, 2020    Sofinnova Partners, a leading European life sciences venture capital firm ba...

Sofinnova Partners Announces Two First Investments from its MD Start III Medtech Acceleration Fund

Investments in innovative medical devices follow the fund’s initial closing in May 2019   PARIS, France – July 2, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the second investment from its MD Start III Fund, a medtech accelerator...

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

1 2